Table 5.

Three-year overall and melanoma specific healthcare costs stratified by stage and presence of prevalent tumors.

		Average daily cost alive patient				Average cost over 3 years after diagnosis
Dataset		Without prevalent tumors	With prevalent tumors	TOTAL	p-value a	Without prevalent tumors	With prevalent tumors	TOTAL	p-value a
All patients (n=2978)	Overall	17.09	32.25	17.73	<0.001	17,471.23	30,698.34	18,066.41	<0.001
	CM-specific	12.83	20.52	13.15	<0.001	13,114.31	19,535.68	13,403.25	<0.001
Stage I (n=2080)	Overall	8.07	24.22	8.7	<0.001	8,698.08	25,161.31	9,362.94	<0.001
	CM-specific	4.84	13.09	5.16	<0.001	5,217.69	13,603.72	5,556.36	<0.001
Stage II (n=396)	Overall	24.4	36.82	25.08	0.013	24,676.67	33,376.11	25,203.91	0.058
	CM-specific	18.85	23.28	19.1	0.239	19,065.74	21,107.9	19,189.51	0.538
Stage III (n=267)	Overall	65.67	67.57	65.78	0.667	64,719.4	64,751.67	64,721.33	0.674
	CM-specific	57.77	57.46	57.75	0.756	56,937.99	55,062.84	56,825.63	0.995
Stage IV (n=126)	Overall	104.01	66.18	102.81	0.643	42,819.87	15,231.01	41,287.15	0.181
	CM-specific	83.41	24.67	81.54	0.038	34,336.56	5,678.16	32,744.43	0.060
Missing (n=109)	Overall	21.94	35.71	22.2	0.985	17,046.81	18,785.66	17,094.67	0.912
	CM-specific	17.15	30.24	17.4	0.760	13,326.63	15,908.54	13,397.69	0.760

^aKruskal–Wallis test. CM, cutaneous melanoma.